Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Nephrology | Urology | Family Medicine
Disease Category: Benign Prostatic Hyperplasia (Enlarged Prostate)
Location: United States, IN
Clinical Trial Details
Research Study Summary
A Phase III multi-center prospective randomized, parallel-group, placebo-controlled, double-blind, clinical evaluation of NX-1207 for the treatment of BPH (Benign Prostatic Hyperplasia, or Enlarged Prostate)
The purpose of this study is to evaluate the efficacy and safety of NX-1207 and to see if it could be useful for men with BPH. The study treatment will consist of either an injection of NX-1207 or of a placebo into the prostate. If you end up receiving the placebo, you will be offered the chance to receive NX-1207 at the end of the study. The study will last for 12 months.
- Male ≥ 45 years of age
- History of BPH for at least 1 year
- Acute or chronic Prostatitis in the past 12 months
- Urinary Tract Infections more than once in the past 12 months
- Previous surgical or invasive prostate treatments such as TURP, TUMT, and TUNA, laser or any minimally invasive treatments.
- History of urinary retention in the past 12 months
- Prostate or bladder cancer
- PSA ≥ 10 ng.ml
To Learn more
Date Last Changed:
May 2, 2014
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.